Meyahealth
HomeGeneticsGeneMED13L gene
Back to Gene
MED13L gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

MED13L gene

The MED13L gene provides instructions for a subunit of the mediator complex, which is essential for regulating gene transcription and early development.

Normal Function

The MED13L gene provides instructions for making a protein that is a subunit of the mediator complex. This complex regulates the activity (transcription) of genes, which is the first step in using DNA to build proteins. The mediator complex physically links transcription factors to RNA polymerase II to initiate transcription.

The MED13L protein is involved in early development, including the formation of the heart, neurons in the brain, and facial structures. It plays a role in chemical signaling pathways that direct cellular activities such as growth, movement (migration), and maturation (differentiation).

Health Conditions Related to Genetic Changes

MED13L syndrome

More than 50 mutations in the MED13L gene have been found to cause MED13L syndrome. This condition is characterized by moderate to severe developmental delay, intellectual disability, and minor facial feature differences. Some individuals also experience epilepsy or congenital heart defects.

  • Some mutations insert or delete DNA, reducing the total amount of MED13L protein.
  • Other mutations change single amino acids, which may act as "dominant-negative" mutations.
  • Dominant-negative mutations impair the function of proteins made from both the altered and normal copies of the gene, often leading to more severe signs than mutations that only affect protein production.

Frequently Asked Questions

Children often show delayed speech, motor skills (rolling, sitting, walking) and social interaction. Early speech‑language therapy, occupational therapy for fine motor skills, and individualized education plans can improve functional outcomes. Regular developmental assessments guide therapy intensity and help families set realistic goals.
Seizure types vary, but many respond to broad‑spectrum antiepileptic drugs such as levetiracetam, valproic acid, or lamotrigine. If seizures are refractory, a trial of ketogenic diet or referral for epilepsy surgery evaluation may be considered. Close monitoring of developmental progress and medication side effects is essential.
Congenital heart defects (e.g., ventricular septal defect, atrial septal defect) are reported in ~30 % of cases. Baseline echocardiography is recommended at diagnosis, followed by periodic assessments (every 1–2 years) or sooner if symptoms (e.g., murmur, exercise intolerance) arise. Electrocardiograms may be added based on clinical findings.
Diagnosis is made by sequencing the MED13L gene (exome or targeted panel). The majority of pathogenic changes are de novo heterozygous missense mutations that act dominantly‑negative, though nonsense, frameshift, or whole‑gene deletions also occur. Parental testing distinguishes inherited from de novo events.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ